Grifols S.A. (NASDAQ:GRFS) does about 1.19M shares in volume on a normal day but saw 2025374 shares change hands in Friday trading. The company now has a market cap of 12.31B USD and an enterprise value of about $24.46B. Its current market price is $17.99, marking a decrease of -2.07% compared to the previous close of $18.37. The 52 week high reached by this stock is $25.73 whilst the lowest price level in 52 weeks is $13.40. The script in recent trading has seen the stock touch a high of $18.35 and a low of $17.80.
Grifols S.A. (GRFS) has a 20-day trading average at $18.83 and the current price is -30.08% off the 52-week high compared with 34.25% distance from its 52-week low. The 50-day simple moving average of the closing price is $19.04 and its 200-day simple moving average is $21.04. If we look at the stock’s price movements over the week, volatility stands at 2.89%, which decreases to 2.58% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 40.48 to suggest the stock is neutral.
FactSet Research has provided data showing that 5 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 4 analysts have rated it as a buy and 1 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 09, 2020 when HSBC Securities upgraded the stock to “Hold” and issued a price target of . Citigroup downgraded the stock to “Sell” from Neutral on June 09, 2020 at a price target of .
The current price level is -4.91%, -5.67%, and -14.57% away from its SMA20, SMA50, and SMA200 respectively, with the GRFS price moving above the 50-day SMA on August 14. Grifols S.A. (GRFS) stock is down -1.37% over the week and -8.82% over the past month. Its price is -22.76% year-to-date and -17.55% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of $0.34 below consensus estimates by -$0.06. GRFS’s earnings per share are forecast to grow by 16.90% this year and 10.10% over next year. Expected sales for next quarter are $1.65 billion, which analysts say will come at $6.43 billion for the current fiscal year and next year at $6.89 billion. In addition, estimates put the company’s current quarterly revenue at an average of $1.59 billion.
Its 12-month price target is $38.64. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $38.64, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $38.64.
Outstanding shares total 684.14M with insiders holding 0.00% of the shares and institutional holders owning 53.68% of the company’s common stock. The price to earnings ratio (P/E ratio) amounts to 30.01 while the forward price to earnings ratio is 11.84. Price to book ratio is 5.06.
According to a U.S. Securities and Exchange Commission filing, First Trust NYSE Arca Biotechnolo has reduced its position in Grifols S.A. (GRFS) to 3,932,384 shares, mirroring a recent drop by 0.00%. First Trust NYSE Arca Biotechnolo dumped 0.0 shares of Grifols S.A. common stock bringing its total worth to about $74.2 million at the end of recent close, SEC documents show. First Trust NYSE Arca Biotechnolo isn’t the only investment manager who changed stakes and is followed by American Funds EuroPacific Growth, which sold off 0.0 shares to end up with 3,513,426 shares worth $66.3 million. Fidelity Funds SICAV – European G raise their holdings by 7.35% in the company over the course of the most recent quarter. It now holds a 0.98% position in Grifols S.A. thanks to 2.56 million shares amounting to $48.26 million.